Since the Luxturna therapy, which is a subretinal surgical delivery of live non-replication adenoviral vector carrying RPE65 gene (Voretigene Neparvovec-rzyl—brand name: LuxturnaTM) (Russell et al. 2017) is available in Poland, it seems that there is a growing interest in performing genetic testing to understand the underlying cause of the LCA, as well as other IRDs, among Polish patients. The gene discussed is RPE65; the disease is respiratory distress syndrome in premature infants.